Tyrosine kinase (TK) inhibitor drugs specifically target BCR-ABL, the constitutively activated tyrosine kinase fusion protein and revolutionized treatment of CML [17]. The gene discussed is BCR; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.